duvelisib
Selected indexed studies
- Duvelisib. (, 2006) [PMID:30371996]
- Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial. (Nat Med, 2024) [PMID:38886623]
- Duvelisib: A comprehensive profile. (Profiles Drug Subst Excip Relat Methodol, 2024) [PMID:38423708]
_Worker-drafted node — pending editorial review._
Connections
duvelisib is a side effect of
Sources
- Duvelisib. (2006) pubmed
- Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial. (2024) pubmed
- Duvelisib: A comprehensive profile. (2024) pubmed
- Duvelisib. (2012) pubmed
- Duvelisib for the treatment of chronic lymphocytic leukemia. (2020) pubmed
- Duvelisib: First Global Approval. (2018) pubmed
- Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma. (2019) pubmed
- Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia. (2017) pubmed
- PMID:40498890 (2022) pubmed
- PMID:40773589 (2021) pubmed